logo

Sage Therapeutics, Inc. (SAGE)



Trade SAGE now with
  Date
  Headline
11/9/2017 6:14:53 AM Sage Therapeutics Says Brexanolone Achieves Primary Endpoints In Both Phase 3 Clinical Trials In Postpartum Depression
11/2/2017 6:36:44 AM Sage Therapeutics Q3 Net Loss Widens To $73.7 Mln From $37.8 Mln Last Year
9/12/2017 6:05:38 AM Sage Therapeutics Says Phase 3 STATUS Trial Of Brexanolone Did Not Achieve Its Primary Endpoint
9/12/2017 6:04:34 AM Sage Therapeutics Says Top-Line Results From Phase 3 STATUS Trial Of Brexanolone In Super-Refractory Status Epilepticus
5/18/2017 7:11:25 AM Sage Therapeutics Gets Fast Track Designation For SAGE-217 For Treatment Of Major Depressive Disorder
4/27/2017 7:27:07 AM Sage Therapeutics Announces Initiation Of Phase 1 Development And First Dosing Of SAGE-718
2/23/2017 6:38:15 AM Sage Therapeutics Q4 Loss Widens To $55.9 Mln Or $1.50/shr From $28.5 Mln Or $0.99/shr Last Year
2/16/2017 7:48:52 PM Sage Therapeutics Says Not In M&A Discussions